GALECTIN THERAPEUTICS INC
Business
Galectin Therapeutics is a clinical-stage biopharmaceutical company developing therapies targeting galectin proteins, which mediate fibrosis, inflammation, and immune dysfunction. Its lead candidate, belapectin (GR-MD-02), is a proprietary complex carbohydrate derived from plant-based starting materials, designed to inhibit galectin-3 for treatment of metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and cancer. The company operates through internal drug development programs and a majority-owned joint venture (Galectin Sciences LLC) pursuing small-molecule galectin-3 inhibitors for oral administration. Clinical development focuses on MASH cirrhosis prevention of esophageal varices and head-and-neck cancer immunotherapy combinations; belapectin is manufactured by third-party suppliers under contract.
Summary from 10-K filed 2026-03-31
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development | 14 | 37 | 32 | 32 | 24 | |
| General and administrative | 6 | 6 | 6 | 7 | 6 | |
| Total operating expenses | 20 | 42 | 38 | 38 | 30 | |
| Total operating loss | −20 | −42 | −38 | −38 | −30 | |
| Interest income | 126,000 | 338,000 | 230,000 | 52,000 | 3,000 | |
| Interest expense | −7 | −6 | −3 | — | — | |
| Change in fair value of derivatives | −4 | 588,000 | −432,000 | 557,000 | 138,000 | |
| Total other expense | −11 | −5 | −3 | −424,000 | −348,000 | |
| Net loss | −31 | −47 | −41 | −39 | −31 | |
| Preferred stock dividends | −138,000 | −153,000 | −120,000 | −97,000 | — | |
| Net loss applicable to common stockholders | −31 | −47 | −45 | −39 | −31 | |
| Net loss per common share - basic (in Dollars per share) | −0.48 | −0.76 | −0.74 | −0.65 | −0.52 | |
| Net loss per common share - diluted (in Dollars per share) | −0.48 | −0.76 | −0.74 | −0.65 | −0.52 | |
| Weighted average common and potential common shares outstanding - basic (in Shares) | 64 | 62 | 60 | 59 | 59 | |
| Weighted average common and potential common shares outstanding - diluted (in Shares) | 64 | 62 | 60 | 59 | 59 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 18 | 15 | 26 | 19 | 40 | |
| Prepaid expenses and other current assets | 2 | 2 | 2 | 2 | 2 | |
| Total current assets | 19 | 17 | 28 | 21 | 42 | |
| Other | 96,000 | 243,000 | 490,000 | 733,000 | 7,000 | |
| Total assets | 20 | 17 | 28 | 21 | 42 | |
| Accounts payable | 3 | 6 | 6 | 4 | 2 | |
| Accrued expenses | 5 | 8 | 9 | 9 | 7 | |
| Current portion of convertible notes payable and accrued interest, net of debt discounts related party (Note 5) | 0 | 21 | 0 | — | — | |
| Current portion of derivative liabilities (Note 6) | 0 | 369,000 | 0 | — | — | |
| Accrued dividends payable | 63,000 | 63,000 | 63,000 | 64,000 | 65,000 | |
| Total current liabilities | 8 | 35 | 16 | 13 | 9 | |
| Convertible notes payable and accrued interest, net of debt discounts related party (Note 5) | 33 | 11 | 31 | 30 | 29 | |
| Derivative liabilities (Note 6) | 4 | 47,000 | 1 | 573,000 | 1 | |
| Borrowing and accrued interest under convertible line of credit, net of debt discount related party (Note 10) | 101 | 74 | 41 | 10 | 0 | |
| Total liabilities | 146 | 121 | 88 | 53 | 39 | |
| Commitments and contingencies (Note 12) | — | — | — | — | — | |
| Series C 6% super dividend redeemable convertible preferred stock; 1,000 shares authorized, 176 issued and outstanding at December 31, 2025 and 2024, redemption value: $7,966,000, liquidation value: $1,760,000 at December 31, 2025 | 2 | 2 | 2 | 2 | 2 | |
| Undesignated stock, $0.01 par value; 20,000,000 shares authorized at December 31, 2025 and 2024, 20,000,000 shares designated at December 31, 2025 and 2024, respectively | 0 | 0 | 0 | 0 | 0 | |
| Series A 12% convertible preferred stock; 1,742,500 shares authorized, 1,210,000 and 1,235,000 issued and outstanding at December 31, 2025 and 2024, respectively, liquidation value $1,210,000 at December 31, 2025 | 490,000 | 500,000 | 500,000 | 510,000 | 527,000 | |
| Common stock, $0.001 par value; 150,000,000 shares authorized at December 31, 2025 and 2024, 65,201,995 and 63,157,235 issued and outstanding at December 31, 2025 and 2024, respectively | 65,000 | 62,000 | 61,000 | 59,000 | 59,000 | |
| Additional paid-in capital | 304 | 296 | 292 | 275 | 271 | |
| Accumulated deficit | −433 | −402 | −354 | −310 | −271 | |
| Total stockholders deficit | −128 | −105 | −62 | −34 | 893,000 | |
| Total liabilities, redeemable convertible preferred stock and stockholders deficit | 20 | 17 | 28 | 21 | 42 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Amortization of right to use asset | 53,000 | 37,000 | 33,000 | 32,000 | 41,000 | |
| Stock-based compensation expense | 2 | 2 | 2 | 3 | 2 | |
| Non-cash interest expense | 1 | 1 | 697,000 | 410,000 | 283,000 | |
| Change in fair value of derivatives | 4 | −588,000 | 432,000 | −557,000 | −138,000 | |
| Prepaid expenses and other assets | 416,000 | −82,000 | −90,000 | 101,000 | 65,000 | |
| Accrued interest on convertible notes payable and convertible line of credit related party | 6 | 4 | 2 | 623,000 | 206,000 | |
| Accounts payable, accrued expenses and other liabilities | −6 | −2 | 3 | 4 | 4 | |
| Net cash from operating activities | −24 | −42 | −33 | −31 | −24 | |
| Net cash from investing activities | 0 | 0 | 0 | 0 | 0 | |
| Net proceeds from convertible line of credit related party | 21 | 30 | 30 | 10 | 0 | |
| Net proceeds from issuance of common stock | 3 | 0 | — | 0 | 7 | |
| Net proceeds from exercise of common stock options and warrants | 2 | 1 | 10 | 0 | — | |
| Net cash from financing activities | 26 | 31 | 40 | 10 | 37 | |
| NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | 3 | −11 | 7 | −21 | 13 | |
| Payment of preferred stock dividends in common stock | 138,000 | 91,000 | 120,000 | 97,000 | 171,000 | |
| Common stock purchase warrants issued in connection with related party line of credit | 667,000 | 845,000 | 671,000 | 899,000 | 0 | |
| Noncash right to use lease asset | 61,000 | 0 | 0 | 111,000 | 0 | |
| Conversion of Series A preferred to common stock | 10,000 | 0 | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is GALECTIN THERAPEUTICS INC's CIK number?
GALECTIN THERAPEUTICS INC's SEC CIK number is 0001133416 (1133416). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find GALECTIN THERAPEUTICS INC's SEC filings?
All of GALECTIN THERAPEUTICS INC's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did GALECTIN THERAPEUTICS INC last report earnings?
GALECTIN THERAPEUTICS INC (GALT) most recently filed an earnings 8-K with the SEC on May 15, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001140361-26-021496). This is GALECTIN THERAPEUTICS INC's most recent earnings filing of record — not a forecast of its next earnings date.
What is GALECTIN THERAPEUTICS INC's most recent earnings 8-K?
GALECTIN THERAPEUTICS INC's latest earnings 8-K (Item 2.02) was filed May 15, 2026 under accession 0001140361-26-021496. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View GALECTIN THERAPEUTICS INC's latest earnings 8-K →
Look up any company's CIK number →